US · PBYI
Puma Biotechnology, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Los Angeles, CA 90024
- Website
- pumabiotechnology.com
Price · as of 2025-12-31
$7.49
Market cap 287.23M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $30.40 | +305.87% |
| Intrinsic Value(DCF) | $12.17 | +62.48% |
| Graham-Dodd Method(GD) | $5.72 | -23.67% |
| Graham Formula(GF) | $4.46 | -40.41% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $28.67 | $73.95 | |||
| 2013 | $112.33 | ||||
| 2014 | $238.39 | ||||
| 2015 | $48.56 | ||||
| 2016 | $40.05 | ||||
| 2017 | $80.75 | $0.00 | $0.00 | ||
| 2018 | $38.20 | $132.12 | $0.00 | $0.00 | $0.00 |
| 2019 | $10.47 | $72.88 | $36.55 | $0.00 | $0.00 |
| 2020 | $11.29 | $40.58 | $0.00 | $0.00 | $12.90 |
| 2021 | $2.63 | $67.24 | $0.00 | $0.00 | $0.00 |
| 2022 | $2.59 | $60.71 | $0.00 | $0.48 | $0.00 |
| 2023 | $5.35 | $20,958.02 | $0.94 | $3.42 | $5.21 |
| 2024 | $3.51 | $26.30 | $1.73 | $5.01 | $3.75 |
| 2025 | $6.42 | $30.40 | $2.61 | $5.72 | $4.46 |
AI valuation
Our deep-learning model estimates Puma Biotechnology, Inc.'s (PBYI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $30.40
- Current price
- $7.49
- AI upside
- +305.87%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$12.17
+62.48% upside
Graham-Dodd
$5.72
-23.67% upside
Graham Formula
$4.46
-40.41% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PBYI | Puma Biotechnology, Inc. | $7.49 | 287.23M | +306% | +62% | -24% | -40% | 10.32 | 2.46 | 1.41 | 4.73 | — | 3.61 | 74.53% | 16.33% | 13.62% | 27.97% | 51.23% | 14.48% | 0.22 | 5.63 | 2.00 | 1.86 | -0.02 | -161.00% | -91.00% | 738.00% | 13.00% | 0.51 | 65.93% | 0.00% | 0.00% | 1.85% | 6.76 | 6.04 | 1.10 | -3.99 |
| ABEO | Abeona Therapeutics Inc. | $5.12 | 277.46M | +447% | — | — | — | -3.32 | 4.81 | — | -2.42 | — | 4.81 | 0.00% | — | — | -216.57% | 205.01% | -73.71% | 0.52 | -15.26 | 6.08 | 5.99 | 0.01 | -3874.00% | -10000.00% | 5656.00% | -27.60% | -3.38 | 186.65% | 0.00% | 0.00% | 0.00% | -2.14 | -2.35 | — | -9.51 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| AVIR | Atea Pharmaceuticals, Inc… | $4.68 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| ELDN | Eledon Pharmaceuticals, I… | $2.62 | 157.07M | — | — | — | — | -5.08 | 1.56 | — | -1.26 | — | 2.15 | 0.00% | — | — | -57.73% | 218.52% | -27.16% | 0.01 | — | 12.42 | 12.11 | 0.55 | -5427.00% | — | 1959.00% | -25.69% | -4.08 | 146.36% | 0.00% | 0.00% | 8.35% | -0.63 | -0.95 | — | -1.36 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| SGMT | Sagimet Biosciences Inc. | $5.71 | 177.02M | +358% | — | — | — | -2.53 | 0.74 | — | 0.79 | — | 0.74 | 0.00% | — | — | -36.92% | -12575.98% | -35.46% | 0.00 | — | 34.30 | 33.96 | 1.66 | -523.00% | -10000.00% | 7855.00% | -36.78% | -9.53 | -9800.23% | 0.00% | 0.00% | 0.60% | 0.66 | 0.84 | — | 12.95 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
- CEO
- Alan H. Auerbach
- Employees
- 172
- Beta
- 1.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($12.17 ÷ $7.49) − 1 = +62.48% (DCF, example).